Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2373
    -0.0065 (-0.52%)
     
  • Bitcoin GBP

    52,208.04
    -58.33 (-0.11%)
     
  • CMC Crypto 200

    1,346.16
    +33.54 (+2.55%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Global Human Vaccines Market to Reach $71.4 Billion by 2030

ReportLinker
ReportLinker

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Human Vaccines Industry" - https://www.reportlinker.com/p06049538/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Human Vaccines Market to Reach $71.4 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Human Vaccines estimated at US$40.2 Billion in the year 2022, is projected to reach a revised size of US$71.4 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2022-2030. Intramuscular & Subcutaneous, one of the segments analyzed in the report, is projected to record a 8% CAGR and reach US$58.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Oral segment is readjusted to a revised 5.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $10.9 Billion, While China is Forecast to Grow at 12.1% CAGR

The Human Vaccines market in the U.S. is estimated at US$10.9 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$16.8 Billion by the year 2030 trailing a CAGR of 12.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 7.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$9.9 Billion by the year 2030.

Select Competitors (Total 16 Featured)
- ALK - Abelló A/S
- Altimmune, Inc.
- Astellas Pharma Inc.
- Bavarian Nordic A/S
- Bharat Biotech
- BiondVax Pharmaceuticals Ltd.
- GlaxoSmithKline Plc
- Hualan Biological Engineering Inc.
- Janssen Pharmaceuticals Inc.
- MedImmune
- Mitsubishi Tanabe Pharma
- Pfizer Inc.
- Sanofi Pasteur SA
- Seqirus
- Serum Institute of India Pvt. Ltd.
- SK BioScience
- Takeda Pharmaceutical Company Limited
- Zydus Cadila


Read the full report: https://www.reportlinker.com/p06049538/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Human Vaccines: A Prelude
Recent Market Activity
Competitive Scenario
Vaccine Pricing: A Review
Human Vaccines - Global Key Competitors Percentage Market Share
in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS
ALK - Abelló A/S (Denmark)
Altimmune, Inc. (USA)
Astellas Pharma Inc. (Tokyo)
Bavarian Nordic (Denmark)
BiondVax Pharmaceuticals Ltd. (Israel)
Bharat Biotech (India)
GlaxoSmithKline Plc. (UK)
Hualan Biological Engineering Inc. (China)
Janssen Pharmaceuticals, Inc. (USA)
MedImmune (USA)
Merck Sharp & Dohme Corp., (USA)
Mitsubishi Tanabe Pharma Corporate (Japan)
Pfizer, Inc. (USA)
Sanofi Pasteur SA (France)
Serum Institute of India Pvt. Ltd. (India)
Seqirus (UK)
SK BioScience (Korea)
Takeda Pharmaceutical Company Limited (Japan)
Zydus Cadila (India)

3. MARKET TRENDS & DRIVERS
Combination Vaccines Market Driven by Fast Expanding Pediatric
Population
List of Combination Vaccines in the US: 2018
Gardasil 9 Offers Protection against HPV for Expanded Age Group
Increasing Demand for Recombinant Vaccines
Global Cholera Vaccines Market
Further Clinical Trials Needed for an Effective Zika Vaccine
Merck’s rVSV-ZEBOV Ebola Vaccine used for Ring Vaccination in
Congo
Rising Dengue Cases Drive Vaccines Demand
Sanofi’s Dengue Vaccine First-to-Market
EMA Recommends Approval of Dengue Vaccine
Vaccine for AIDS
Staggering Global Statistics of AIDS - Opportunity Indicator
Toxoid Vaccines Market
H1N1 Vaccines Market
HSV Vaccine on the Horizon
Rising Disease Incidence and Increasing Awareness Drive the
Global Meningococcal Vaccines Market
BCG Vaccines
Key TB Vaccine Candidates in the Pipeline: 2018
New Vaccine for Herpes Zoster or Shingles
Two-dose Hepatitis B Vaccine for Adults
Global Rotavirus Vaccines Market
Typhoid Vaccines Market
Measles Vaccines Market
DNA Vaccines: Engineering Growth
Mobile Money Encourages Parents for Vaccinating Children
Noninjectable Vaccines: Gain without Pain
Application of Botulinum Toxin as Delivery Mechanism for Oral
Vaccines
Novel Technologies Ensure Timely Vaccine Delivery for Patients
in Remote Locations
Smart mRNA Vaccines
Growing Pricing Pressure - A Major Market Deterrent
Safety Issues Come to the Fore
Novel Vaccination Guidelines Mitigate Risks Associated with
Developing Shoulder Injuries
BioWarfare: Threat Perception and Preparedness
Overview of Potential Bio-Terrorist Agents
Smallpox (Variola Major)
Anthrax (Bacillus Anthracis)
Plague (Yersinia Pestis)
Botulism (Clostridium Botulinum)
Tularemia (Francisella Tularensis)
Tackling Cold Chain Issues
Trade Statistics
Growing Incidence of Infectious Diseases Drives the Global
Human Vaccines Market
Total Number of Infectious Disease Covered under Vaccination 1
Conjugate Vaccines Rule in Human Vaccines Market
Pneumococcal Vaccines - A Major Segment
Vaccine Pipeline by Major Companies
GSK Vaccine Pipeline
Merck Vaccines Pipeline
Pfizer Vaccines Pipeline
Sanofi Vaccines Portfolio
Emergent BioSolutions Inc. - Vaccine Pipeline
Astellas Pharma - Vaccines
Pediatric Vaccines Dominate the Human Vaccines Market
Select Pediatric Vaccines
Adults Vaccine Market to Witness Rapid Growth, Driven by
Government Initiatives
Select Adult Vaccines
Developed Markets Dominate, Emerging Regions to Exhibit the
Fastest Growth
Pneumococcal Vaccines Market Set to Witness Rapid Growth
Influenza Vaccines Market: A High Growth Segment
Cancer Vaccines Market Offers Potential Opportunities

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Human
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Human Vaccines by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 3: World 16-Year Perspective for Human Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Intramuscular & Subcutaneous by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Intramuscular & Subcutaneous
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 6: World 16-Year Perspective for Intramuscular &
Subcutaneous by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for Oral
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 8: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 9: World 16-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Other Administration Routes by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Other Administration Routes
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 12: World 16-Year Perspective for Other Administration
Routes by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 13: World Recent Past, Current & Future Analysis for
Conjugate by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Conjugate by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 15: World 16-Year Perspective for Conjugate by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Recombinant by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Recombinant by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 18: World 16-Year Perspective for Recombinant by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Inactivated & Subunit by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Inactivated & Subunit by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Inactivated & Subunit
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for Live
Attenuated by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Live Attenuated by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Live Attenuated by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Other Technologies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Human Vaccines Market Analysis of Annual Sales
in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2023 (E)
Table 29: USA Recent Past, Current & Future Analysis for Human
Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 30: USA Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR 1

Table 31: USA 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 32: USA Recent Past, Current & Future Analysis for Human
Vaccines by Technology - Conjugate, Recombinant, Inactivated &
Subunit, Live Attenuated and Other Technologies - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 33: USA Historic Review for Human Vaccines by Technology -
Conjugate, Recombinant, Inactivated & Subunit, Live
Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 34: USA 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 36: Canada Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 37: Canada 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 38: Canada Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 39: Canada Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 40: Canada 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

JAPAN
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2023 (E)
Table 41: Japan Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 42: Japan Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 43: Japan 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 44: Japan Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 45: Japan Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 46: Japan 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

CHINA
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2023 (E)
Table 47: China Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 48: China Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 49: China 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 50: China Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 51: China Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 52: China 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

EUROPE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2023 (E)
Table 53: Europe Recent Past, Current & Future Analysis for
Human Vaccines by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 54: Europe Historic Review for Human Vaccines by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 55: Europe 16-Year Perspective for Human Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030

Table 56: Europe Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 57: Europe Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 58: Europe 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 60: Europe Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 61: Europe 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

FRANCE
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2023 (E)
Table 62: France Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 63: France Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 64: France 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 65: France Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 66: France Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 67: France 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

GERMANY
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2023 (E)
Table 68: Germany Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 69: Germany Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 70: Germany 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 71: Germany Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 72: Germany Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 73: Germany 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

ITALY
Table 74: Italy Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 75: Italy Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 76: Italy 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 77: Italy Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 78: Italy Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 79: Italy 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

UNITED KINGDOM
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2023 (E)
Table 80: UK Recent Past, Current & Future Analysis for Human
Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 81: UK Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 82: UK 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 83: UK Recent Past, Current & Future Analysis for Human
Vaccines by Technology - Conjugate, Recombinant, Inactivated &
Subunit, Live Attenuated and Other Technologies - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 84: UK Historic Review for Human Vaccines by Technology -
Conjugate, Recombinant, Inactivated & Subunit, Live Attenuated
and Other Technologies Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 85: UK 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

SPAIN
Table 86: Spain Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 87: Spain Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 88: Spain 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 89: Spain Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 90: Spain Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 91: Spain 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

RUSSIA
Table 92: Russia Recent Past, Current & Future Analysis for
Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 93: Russia Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 94: Russia 16-Year Perspective for Human Vaccines by
Administration Route - Percentage Breakdown of Value Sales for
Intramuscular & Subcutaneous, Oral and Other Administration
Routes for the Years 2014, 2023 & 2030

Table 95: Russia Recent Past, Current & Future Analysis for
Human Vaccines by Technology - Conjugate, Recombinant,
Inactivated & Subunit, Live Attenuated and Other Technologies -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 96: Russia Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 97: Russia 16-Year Perspective for Human Vaccines by
Technology - Percentage Breakdown of Value Sales for Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies for the Years 2014, 2023 & 2030

REST OF EUROPE
Table 98: Rest of Europe Recent Past, Current & Future Analysis
for Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Table 99: Rest of Europe Historic Review for Human Vaccines by
Administration Route - Intramuscular & Subcutaneous, Oral and
Other Administration Routes Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2014 through 2021 and %
CAGR

Table 100: Rest of Europe 16-Year Perspective for Human
Vaccines by Administration Route - Percentage Breakdown of
Value Sales for Intramuscular & Subcutaneous, Oral and Other
Administration Routes for the Years 2014, 2023 & 2030

Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Human Vaccines by Technology - Conjugate,
Recombinant, Inactivated & Subunit, Live Attenuated and Other
Technologies - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Human Vaccines by
Technology - Conjugate, Recombinant, Inactivated & Subunit,
Live Attenuated and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 103: Rest of Europe 16-Year Perspective for Human
Vaccines by Technology - Percentage Breakdown of Value Sales
for Conjugate, Recombinant, Inactivated & Subunit, Live
Attenuated and Other Technologies for the Years 2014, 2023 &
2030

ASIA-PACIFIC
Human Vaccines Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Asia-Pacific for 2023 (E)
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Human Vaccines by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 105: Asia-Pacific Historic Review for Human Vaccines by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2014 through 2021 and % CAGR

Table 106: Asia-Pacific 16-Year Perspective for Human Vaccines
by Geographic Region - Percentage Breakdown of Value Sales for
Australia, India, South Korea and Rest of Asia-Pacific Markets
for Years 2014, 2023 & 2030

Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Human Vaccines by Administration Route - Intramuscular &
Subcutaneous, Oral and Other Administration Routes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06049538/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001